Lupin Gains 16% in a Month. Here's Why it Could Rally More - Views on News from Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks


Login Failure
(Please do not use this option on a public machine)
  Sign Up | Forgot Password?  
  • Home
  • Views On News
  • Jun 4, 2021 - Lupin Gains 16% in a Month. Here's Why it Could Rally More

Lupin Gains 16% in a Month. Here's Why it Could Rally More

Jun 4, 2021

Amid the ongoing second wave, Indian pharma companies are witnessing a rise in their volumes, given that they are the world's biggest bulk drug exporters.

India exports roughly 20% of the world's generic drugs.

For the month of April 2021, India's pharma industry witnessed a strong growth to 59% as compared to 16% year on year growth in March 2021.

This was due to the low base effect in April 2020 and sharp surge in Covid-19-related sales.

Amid all this, a pharma major in which Rakesh Jhunjhunwala holds stake, has caught investor's fancy.


Lupin enters digital healthcare business

On Thursday, Lupin announced that it has entered into the digital healthcare business.

The entry into the space is with a focus to provide a digital therapeutics platform for doctors and patients in India.

Recently, the company had incorporated a new entity in the name of Lupin Digital Health, as a wholly owned subsidiary, which will undertake this.

--- Advertisement ---
This is a Powerful Mega Trend Playing Out in India

We have uncovered a powerful mega trend that is playing out in India right now.

It could potentially generate immense wealth for early movers.

Our co-head of research Tanushree Banerjee has also zeroed in on one specific stock riding this mega trend.

It's her #1 stock pick right now.

And she believes, this could be one of the top stocks to get to potential Rs 7 crore wealth over the long term.

Tanushree will reveal all the details about this mega trend and her #1 stock at her special online event on July 29.

At the event Tanushree will also show you, how to potentially accumulate Rs 7 crore in wealth over the long term.

What you learn at the event could possibly change your financial fortunes forever.

Click here to reserve your FREE seat.

Lupin's vaccine partnership

Last month, Lupin CEO Vinita Gupta had said the company is working on acquiring licenses and partnerships for various Covid-19 drugs.

This vaccines after the drug maker missed out on launching drugs in the first wave of the pandemic.

The company is also exploring partnerships with Pfizer and Moderna for their Covid-19 vaccines, Gupta said.

The company recently entered a licensing pact with Eli Lilly for Baricitinib, a drug which can be used in the treatment of Covid-19.

But this is expected to take at least a couple of months to launch.

Recent Announcements

On Wednesday this week, Lupin announced that the United States Food and Drug Administration (USFDA) has accepted the Biologics License Application (BLA) for its proposed biosimilar to Neulasta (pegfilgrastim) through a filing using the 351(k) pathway.

Pegfilgrastim has estimated annual sales of US$3.66 bn in the US.

Last month on 27 May Lupin announced the achievement of key milestones for its MEK inhibitor compound.

This compound is planned for development by Boehringer Ingelheim in combination as potential targeted therapy for patients with difficult to treat cancers.

As part of the agreement, Lupin has received payment of US$50 m from Boehringer Ingelheim.

On the results front, Lupin turned profitable with a profit of Rs 12.2 bn for the financial year ended March 2021 against a loss of Rs 2.7 bn in the previous fiscal.

Free Signup: The Smallcap Revival Summit

In the March quarter, its bottomline rose to Rs 4.6 bn against Rs 3.9 bn in the corresponding period of the previous fiscal.

Key Positives for Lupin

Lupin has been consistently reducing its debt for the past few years. This is evident from the chart below.

Lupin also has strong free cash flows to the tune of Rs 11,531 m as of March 2021.

Moreover, the company continues to consolidate its position in the US as well as India.

Robust India Business

As of March 2021, ace investor Rakesh Jhunjhunwala held 7.2 m shares or 1.6% stake in Lupin.

Mutual funds held 13.05% stake or 59.2 m shares while foreign portfolio investors (FPIs) held 17.87% stake or 81 m shares.

Promoters stake stood at 46.58%.

--- Advertisement ---
How Fund Managers Spot Winning Stocks

Fund managers don't buy stocks on a whim. They buy only when they can get the best price in the market.

By using Wyckoff Accumulation Analysis, you can get the same edge as fund managers.

Watch this video to learn how to spot winning stocks like fund managers.

Equitymaster's View on the Pharma Sector

We reached out to Tanushree Banerjee, Co-Head of Research at Equitymaster, and editor of the premium stock recommendation service StockSelect, for her view on the pharma sector.

Here's what she has to say...

  • The second Covid wave has given a new lease of life to pharma stocks. As the sector continues to invest in capacities for new drugs, the profitability will depend on the companies' ability to seek USFDA approval for the plants.

    Or their ability to tie up with MNC pharma for producing variants of their vaccine.

How Shares of Lupin are Performing Today

Lupin share price pared early gains of 1% and settled the day on a flat note.

Lupin shares have a 52-week high quote of Rs 1,268 touched earlier this week on 2 June and a 52-week low quote of Rs 829 touched on 27 July 2020.

Over the last 30 days, Lupin shares are up 16%. Over the last one year, the shares have gained 42%.

The stock is on a rise amid expectations of healthy growth in the near term.

The rise can also be attributed to several brokerages raising targets for the stock after Lupin's 18% growth in net profit.

However, one thing to note is that the stock is still much below its all-time high levels of Rs 2,100, even after the second wave of Covid-19.

Going forward, analysts believe that its margins are expected to improve as the company's business in generic drug segment in the US and Europe increases.

At its current price, it is trading at a P/E of 44.5.

The company commands a market-cap of Rs 560.3 bn.

About Lupin

Lupin was founded in 1968 by the late Dr Desh Bandhu Gupta, the father of the current managing director, Mr Nilesh Gupta, when Dr Gupta had bought the Lupin trademark from Charak Pharmaceuticals.

Set up originally as a proprietary concern, Lupin was converted into a private limited company in 1972 and became a public limited company in 1992.

In June 2001, it was merged with Lupin Laboratories, following which the merged entity was renamed as Lupin. The amalgamation was aimed at leveraging the strengths of the two companies.

Lupin is an integrated pharma company with a presence across research, manufacturing and marketing of formulations and APIs.

The company's business mix can be broadly divided into two segments - formulations and APIs.

For more details about the company, you can have a look at Lupin company factsheet and Lupin quarterly results on our website.

For a sector overview, read our pharmaceuticals sector report.

You can also compare Lupin with its peers.

Lupin vs Aurobindo Pharma

Lupin vs Biocon

Lupin vs Alembic Pharma

Lupin vs Cipla

Lupin vs Dr Reddy's Lab

To know what's moving the Indian stock markets today, check out the most recent share market updates here.

Equitymaster requests your view! Post a comment on "Lupin Gains 16% in a Month. Here's Why it Could Rally More". Click here!


More Views on News

LUPIN 2019-20 Annual Report Analysis (Annual Result Update)

Dec 7, 2020 | Updated on Dec 7, 2020

Here's an analysis of the annual report of LUPIN for 2019-20. It includes a full income statement, balance sheet and cash flow analysis of LUPIN. Also includes updates on the valuation of LUPIN.

LUPIN Announces Quarterly Results (2QFY21); Net Profit Up 271.3% (Quarterly Result Update)

Nov 6, 2020 | Updated on Nov 6, 2020

For the quarter ended September 2020, LUPIN has posted a net profit of Rs 2 bn (up 271.3% YoY). Sales on the other hand came in at Rs 38 bn (down 12.0% YoY). Read on for a complete analysis of LUPIN's quarterly results.

LUPIN Announces Quarterly Results (1QFY21); Net Profit Down 64.2% (Quarterly Result Update)

Aug 18, 2020 | Updated on Aug 18, 2020

For the quarter ended June 2020, LUPIN has posted a net profit of Rs 1 bn (down 64.2% YoY). Sales on the other hand came in at Rs 35 bn (down 20.2% YoY). Read on for a complete analysis of LUPIN's quarterly results.

What's Behind the Rally in Pharma Stocks? (Views On News)

May 11, 2021

The second wave of Covid has given a new lease of life to pharma stocks.

Glenmark Life Sciences IPO Opens Tomorrow: Few Points to Know Before Applying (Views On News)

Jul 26, 2021

All you need to know about the IPO of Glenmark Life Sciences.

More Views on News

Most Popular

All You Need to Know About Primary and Secondary Markets

A look at the various types of primary and secondary markets and the key differences between them.

RBI Opens a New Market for Investors (Fast Profits Daily)

Jul 16, 2021

You now have a new way to create wealth. Grab it with both hands.

A Better Way than the Zomato IPO to Play the Food Delivery Megatrend (Profit Hunter)

Jul 14, 2021

A unique backdoor way of making big profits from smallcap companies.

These Are the Best Stocks to Own (Fast Profits Daily)

Jul 22, 2021

Find out what I think are the best kind on stocks to own in the market.

Heads Up Bank Nifty Traders (Fast Profits Daily)

Jul 14, 2021

The RBI raised bond yields on 10yr benchmark paper. That can impact Bank Nifty traders in the coming days.


Become A Smarter Investor
In Just 5 Minutes

Multibagger Stock Guide 2021
Get our special report Multibagger Stocks Guide (2021 Edition) Now!
We will never sell or rent your email id.
Please read our Terms


Jul 26, 2021 (Close)